


## 2. Introduction to Molecular Biotechnology


Bi7430 Molecular Biotechnology

|   | Outline   |
|---|---|
|   | <ul> <li>Definition of biotechnology</li> </ul> |
|   | ☐ History of biotechnology                      |
|   | ☐ Fundamentals of molecular biotechnology       |
|   | ☐ Basic concept of rDNA technology              |
|   | ☐ Methods of gene transfer                      |
|   | ☐ Main fields of biotech applications           |
|   | ☐ Risks and positives                           |
| ı |   |

## Definition of biotechnology










(The United Nations Convention on Biological Diversity, 1992)


| • |  |  |
|---|--|--|
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |
|   |  |  |






















| His | story o | of biotechnology  |
|-----|---------|---|
|     | MOL     | ECULAR BIOTECHNOLOGY REVOLUTION   |
|     | 1973    | Stanley Kohen and Herbert Boyer - development of recombinant DNA technology   |
|     | 1976    | Herbert Boyer and Robert Swanson  |
|     | 1978    | production of <b>human insulin</b> in <i>E. coli</i> by Genentec  (recombinant "human" insulin approved by FDA 1982)    |
|     | 1981    | production of recombinant growth hormone  |
|     | 1987    | production of recombinant <b>tissue plasminogen activator</b> used to dissolve blood clots during myocardial infarction |
|     | 1980-83 | about 200 small biotechnological companies founded in US  |
















| Pi | os and cons  |  |
|----|--|--|
|    |  | nes, creating new life forms "playing God"?                                      |
|    | <ul> <li>will transgenic organisms be h</li> <li>should humans be genetically</li> </ul> | armfull to other organism or environment?<br>engineered?                         |
|    | ositive aspects of molecular   | • •  |
|    | infectious and genetic <b>disease</b>  |  |
|    | <ul> <li>increase crop yield and resi<br/>stress (e.g., drought, heat, co</li> </ul>     | stence to insects and diseases, environmental<br>d)                              |
|    |  | roduce chemicals in sustainable manner  its and waste materials from environment |
|    |  |  |